Evidence map›Paper›PMID 38136323›Full record

ArticleCancers2023

Association of

Katja Zappe, Katharina Pühringer, Simon Pflug, Daniel Berger, Serge Weis, Sabine Spiegl-Kreinecker, Margit Cichna-Markl

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Cells · 2026
    Article
  2. Association of Intergenic and IntragenicInternational journal of molecular sciences · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Katja ZappeDepartment of Analytical Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria.ORCID 0000-0003-2002-9727
Katharina PühringerDepartment of Analytical Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria.
Simon PflugDepartment of Analytical Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria.ORCID 0000-0003-3421-2346
Daniel BergerDepartment of Analytical Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria.
Serge WeisDivision of Neuropathology, Department of Pathology and Molecular Pathology, Kepler University Hospital GmbH, Johannes Kepler University, 4040 Linz, Austria.ORCID 0000-0001-6750-2599
Sabine Spiegl-KreineckerDepartment of Neurosurgery, Kepler University Hospital GmbH, Johannes Kepler University, 4040 Linz, Austria.
Margit Cichna-MarklDepartment of Analytical Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria.ORCID 0000-0001-8699-674X
University of Vienna · ATKepler Universitätsklinikum · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The response of glioblastoma (GBM) patients to the alkylating agent temozolomide (TMZ) vitally depends on the expression level of the repair protein O6-methylguanine-DNA methyltransferase (MGMT). Since MGMT is strongly regulated by promoter methylation, the methylation status of the

Indexed as

agebiomarkerDNA methylationenhancer methylationglioblastomaKi-67MGMToverall survivalpromoter methylation

Identifiers

PMID38136323
PMCPMC10742072
OpenAlexW4389545954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.